Esco Lifesciences Group Completes Acquisition of Esco Korea Micro Ltd
Acquiring Esco's distributor in South Korea is set to improve our outreach by establishing direct sales and service teams to serve the expanding market in the region.
Digital transformation initiatives will enhance efficiency and productivity following the asset transfers.
SOUTH KOREA, 20 September 2024 - Esco Lifesciences Group is pleased to announce the successful acquisition of its distributor, Esco Korea Micro Ltd., through a newly formed subsidiary, Esco Lifesciences Korea Co., Ltd. in South Korea (“Esco Korea”). The acquisition marks a significant milestone, and Esco Korea is set to begin operations on 1 October 2024.
This strategic move aims to strengthen Esco Lifesciences Group's distribution capabilities by establishing direct sales and service teams to meet the demands of the growing biopharma, research, and clinical markets in South Korea. By consolidating resources, the acquisition is expected to improve operational efficiency and support expansion in the region.
Esco Lifesciences Group also plans to leverage this acquisition to advance digital transformation within Esco Lifesciences Korea Co., Ltd. This includes streamlining accounting management, customer relationship management, and other operational areas. Additionally, human capital development will be a focus, with plans to provide training to ensure employees are equipped to adapt to the company’s digitalization efforts.
“With the acquisition of Esco Korea Micro Ltd., we are taking a big step toward enhancing our footprint in the region. This strategic move also accelerates our efforts in digital transformation, allowing us to operate more efficiently while expanding our impact. We are committed to fostering innovation and growth, empowering our teams, and delivering even greater value to our customers as we shape the future of life sciences together,” said XQ Lin, Chief Executive Officer.
We are excited about the future potential this acquisition holds and are confident that it will help Esco Lifesciences Group achieve its goal of becoming a leader in its field.
